학술논문
Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)
Document Type
Abstract
Author
Source
In Cytotherapy May 2019 21(5) Supplement:e2-e3
Subject
Language
ISSN
1465-3249